<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514692</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-56842</org_study_id>
    <secondary_id>GYN0007</secondary_id>
    <nct_id>NCT04514692</nct_id>
  </id_info>
  <brief_title>Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging</brief_title>
  <official_title>Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow&#xD;
      stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of&#xD;
      growth factor. Growth factors are proteins made in the body. G-CSF is a type of growth factor&#xD;
      that makes the bone marrow produce white blood cells to reduce the risk of infection after&#xD;
      some types of cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1 and 2 study. The phase I is a dose finding portion of the study and phase 2&#xD;
      will enroll additional patients at the dose found in phase I. Patients in phase I and phase 2&#xD;
      will have the same treatment and followup.&#xD;
&#xD;
      Participants will undergo standard of care diagnostic imaging, complete blood count (CBC)&#xD;
      with differential and chemistry labs initially. While receiving the GCSF, participants will&#xD;
      have a CBC with differential checked a day after each dose and one day prior to first day of&#xD;
      radiation. The treatment planning FDG PET/CT will be performed shortly after the GCSF. During&#xD;
      chemoradiation, participants will have weekly CBC with differential checked and other labs as&#xD;
      standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Recommended phase 2 dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>Recommended phase 2 dose (RP2D) will be defined as the dose at which the standard uptake value (SUV) on D5 FDG PET reaches target SUVmean of 2.5 or higher with normalization of white blood cells (WBC) and ANC prior to start of radiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the rate of grade 3 or greater neutropenia (ANC &lt; 1000/mm3 at any point of therapy)</measure>
    <time_frame>33 months</time_frame>
    <description>Rate of grade 3 or greater neutropenia (ANC &lt; 1000/mm3 at any point of therapy) will be monitored by the regular CBC with differential on the study schema and calendar, as per standard of care for patients receiving chemoradiation and/or chemotherapy.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Cervix Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I -Dose finding, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I -Dose finding, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I -Dose finding, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II-G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG PET/CT</intervention_name>
    <description>Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)</description>
    <arm_group_label>Phase I -Dose finding, Cohort 1</arm_group_label>
    <arm_group_label>Phase I -Dose finding, Cohort 2</arm_group_label>
    <arm_group_label>Phase I -Dose finding, Cohort 3</arm_group_label>
    <arm_group_label>Phase II-G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCSF</intervention_name>
    <description>Granulocyte Colony Stimulating Factor (GCSF)</description>
    <arm_group_label>Phase I -Dose finding, Cohort 1</arm_group_label>
    <arm_group_label>Phase I -Dose finding, Cohort 2</arm_group_label>
    <arm_group_label>Phase I -Dose finding, Cohort 3</arm_group_label>
    <arm_group_label>Phase II-G-CSF</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
    <other_name>Zarxio</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2018 international Federation of Gynecology and Obstetrics (FIGO) stage I IIIC1 cervix&#xD;
             cancer with no prior treatment or stage IIIA IIIC1 endometrial cancer status post&#xD;
             hysterectomy and lymph node assessment&#xD;
&#xD;
          -  No required para aortic or extended field radiation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 2&#xD;
&#xD;
          -  Adequate kidney function (serum Cr &lt;1.5 or creatinine clearance &gt;50 mg/dl)&#xD;
&#xD;
          -  Adequate bone marrow function (white blood cells &gt; 3.0 X 109/L, platelets &gt;100 x&#xD;
             109/L)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment for other cancer in the past 2 years&#xD;
&#xD;
          -  Previous pelvic radiation&#xD;
&#xD;
          -  Medical condition that prevents receiving chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Kidd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neha Aidasani</last_name>
    <phone>650-721-4076</phone>
    <email>aidasani@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Aidasani</last_name>
      <phone>650-721-4076</phone>
      <email>aidasani@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth A Kidd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

